Physician profile
Nathan G Asher
NPI 1467626937
$589.39
in general payments reported to CMS, 2019-2025
16 companies · $109 in 2025
The $109 reported for 2025 was more than what a typical Pediatrics provider received nationally (typical 2025 total: $96.93).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $123 · 2020: $23.35 · 2021: $102 · 2022: $76.30 · 2023: $24.49 · 2024: $131 · 2025: $109.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $265.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $264.70 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Pfizer INC. | $112.11 | 2024 | |
| Tris Pharma INC | $94.91 | 2019-2021 | |
| Supernus Pharmaceuticals, INC. | $73.69 | 2022-2025 | Qelbree |
| Ironshore Pharmaceuticals INC. | $49.18 | 2019-2020 | |
| Sanofi-Aventis U.S. LLC | $44.49 | 2024-2025 | |
| Merck Sharp & Dohme LLC | $43.24 | 2021-2025 | Gardasil 9, Vaxelis, Rotateq |
| Vertical Pharmaceuticals, LLC | $28.93 | 2019 | |
| Ns Pharma, INC. | $24.49 | 2023 | Viltepso |
| Acadia Pharmaceuticals INC | $19.25 | 2025 | Daybue |
| Astrazeneca Pharmaceuticals LP | $18.54 | 2022 | |
| Corium, LLC | $16.63 | 2022 | |
| Sobi, INC | $16.07 | 2019 | |
| Adlon Therapeutics L.P. | $12.44 | 2019 | |
| Takeda Pharmaceuticals U.S.A., INC. | $12.13 | 2020 | |
| Kaleo, INC. | $11.75 | 2021 |
Show all 16 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novartis Pharmaceuticals Corporation | $11.54 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Nathan Asher listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.